Clinical Aspects in the Treatment of Elderly Patients with Acute Myeloid Leukemia
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: closed (20 September 2024) | Viewed by 1760
Special Issue Editor
Interests: hematologic diseases; chronic myeloid leukemia (CML); blood disorders; clinical hematology; myelodysplastic syndromes; haematological studies; acute myeloid leukemia
Special Issue Information
Dear Colleagues,
In recent years, the development of new therapies for acute myeloid leukemia (AML) has progressed slowly. For decades, the standard treatment for AML has been intensive induction chemotherapy, sometimes followed by a hematopoietic stem cell transplant. Unfortunately, older patients are less responsive to such aggressive chemotherapy and cannot tolerate it. Since the majority of AML patients are elderly, this group has been most affected by the lack of newer, less-toxic therapies. However, the landscape of AML treatments given to elderly patients has recently changed significantly with the approval of several new drugs.
The aim of this Special Issue is to update the current knowledge on the treatment of elderly patients with AML who are unfit for intensive chemotherapy. We encourage you to submit your scientific article in order to improve our shared knowledge of this topic and implement new approaches in clinical practice.
Dr. Matteo Molica
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute myeloid leukemia
- unfit patients
- non-chemotherapy approaches
- treatment stratification by fitness
- target therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
